Compositions and methods for siRNA inhibition of angiogenesis
AssigneeThe Trustees of the University of Pennsylvania
InventorsMichael J. Tolentino, Samuel Jotham Reich
Life of this patent
Estimating the term…
Abstract
RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve antiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
Claims19
A pharmaceutical composition comprising an effective amount of a double-stranded short interfering ribonucleic acid (siRNA) and a pharmaceutically acceptable carrier, wherein the short interfering ribonucleic acid (siRNA) comprises a sense RNA strand and an antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in human vascular endothelial growth factor (VEGF) mRNA, wherein the nucleotide sequence identical to a target sequence consists of a sequence selected from the group consisting of:
- SEQ ID NO. 13, 19, 20, 47, 48, 50 , 51, 52, 56, 16, 23, 28, 29, 34, 57, 66, 71, 75, 84, and 88.
A pharmaceutical composition comprising an effective amount of a double-stranded short interfering ribonucleic acid (siRNA) and a pharmaceutically acceptable carrier, wherein the short interfering ribonucleic acid (siRNA) comprises a sense RNA strand and an antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human vascular endothelial growth factor (VEGF) mRNA, wherein said effective amount is an amount effective to inhibit the expression of overexpressed VEGF, wherein the nucleotide sequence identical to a target sequence consists of a sequence selected from the group consisting of:
- SEQ ID NO. 13, 19, 20, 47, 48, 50, 51, 52, 56, 16, 23, 28, 29, 34, 57, 66, 71, 75, 84, and 88.
Dependencies are inferred from the claim text.